Triptorelin’s pamoate 3-month formulation simplifies endometriosis management without compromising effectiveness. Designed to reduce treatment frequency, it achieves the same clinical outcomes as the 1-month acetate version, including significant hormone suppression and pain reduction. This alternative reduces healthcare visits and patient burden, maintaining safety and tolerability, as evidenced by comprehensive trials involving Chinese patients with regular cycles requiring GnRH agonist therapy.
Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Triptorelin 2 by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.
Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.
Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.
Li, X., Li, H., Shi, H., Li, X., Zhou, R., Lu, D., Cai, Y., Zhou, Y., Cabri, P., Shi, X., Pedret-Dunn, A., and Leng, J., 2022. Assessment of two formulations of triptorelin in Chinese patients with endometriosis: A phase 3, randomized controlled trial. Advances in Therapy.
Home
